Stock 300639 GUANGDONG HYBRIBIO BIOTECH CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangdong Hybribio Biotech Co.,Ltd.

Equities

300639

CNE100002N51

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6.2 CNY +2.31% Intraday chart for Guangdong Hybribio Biotech Co.,Ltd. +1.47% -33.62%
Apr. 26 Guangdong Hybribio Biotech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 24 Guangdong Hybribio Biotech Co.,Ltd. Proposes Final Dividend for the Year 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company returns high margins, thereby supporting business profitability.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGDONG HYBRIBIO BIOTECH CO.,LTD. Stock Guangdong Hybribio Biotech Co.,Ltd.
-33.62% 546M -
BIOMÉRIEUX Stock bioMérieux
+0.89% 12.8B
B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD. Stock Shenzhen New Industries Biomedical Engineering Co., Ltd.
-10.29% 7.61B
B-
AUTOBIO DIAGNOSTICS CO., LTD. Stock Autobio Diagnostics Co., Ltd.
-1.16% 4.51B
C
LANTHEUS HOLDINGS, INC. Stock Lantheus Holdings, Inc.
+5.74% 4.49B
C
10X GENOMICS, INC. Stock 10x Genomics, Inc.
-50.70% 3.3B
D+
ANDON HEALTH CO., LTD. Stock Andon Health Co., Ltd.
+12.21% 2.73B - -
VITROLIFE AB Stock Vitrolife AB
-16.13% 2.02B
B-
GUANGZHOU WONDFO BIOTECH CO.,LTD Stock Guangzhou Wondfo Biotech Co.,Ltd
-11.50% 1.73B
D+
MYRIAD GENETICS, INC. Stock Myriad Genetics, Inc.
-5.02% 1.64B
C
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300639 Stock
  4. Ratings Guangdong Hybribio Biotech Co.,Ltd.